Polatuzumab

Polatuzumab is a monoclonal antibody that targets CD79b on the surface of B cells. Polatuzumab can be used to synthesize the ADC Polatuzumab Vedotin (HY-132253), which has anti-tumor activity[1].

Product Specifications

CAS Number

[2279068-37-8]

UNSPSC

12352203

Target

ADC Antibody; Transmembrane Glycoprotein

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/polatuzumab.html

Purity

99.69

Solubility

H2O

Smiles

[Polatuzumab]

Molecular Weight

(145.5 kDa)

References & Citations

[1]Estelle Bourbon, et al. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma. Expert Opin Investig Drugs. 2020 Oct;29 (10) :1079-1088.